JAK2基因突变在恶性血液病中的作用
摘要
近年来,人们在多种恶性血液病中发现了JAK2基因突变(V617F)的存在。JAK2V617F在骨髓增殖性疾病及难治性贫血伴环形铁粒幼细胞伴显著血小板增多中较为多见,在急性髓系白血病的部分亚型中亦有不同的发生率。其致病机制至今尚未完全阐明,推测与突变引起JAK—STAT信号通路的持续性活化,继而导致对多种细胞因子的高敏感性相关。JAK2基因突变的临床意义逐渐展露,其有助于骨髓增殖性疾病的诊断和靶向治疗,并且可能对急性髓系白血病的预后判断及临床治疗产生重要意义。本文就近年来有关,JAK2V617F在多种恶性血液病中的相关研究进展作一综述。
出处
《国际输血及血液学杂志》
CAS
2010年第2期143-146,共4页
International Journal of Blood Transfusion and Hematology
参考文献25
-
1James C,Ugo V,Le Couédic JP,et al.A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera.Nature,2005,434(7037):1144-1148.
-
2Rawlings JS,Rosler KM,Harrison DA.The JAK/STAT signaling pat hway.J Cell Sci,2004,117 (8):1281-1283.
-
3Baxter EJ,Scott LM,Campbell PJ,et al.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.Lancet,2005,365 (9464):1054-1061.
-
4Levine RL,Wadleigh M,Cools J,et al.Activating mutation in the tyrosine kinase JAK2 in polycythemia vera,essential thrombocythemia,and myeloid metaplasia with myelofibrosis.Cancer Cell,2005,744):387-397.
-
5Kralovics R,Passamonti F,Buser AS,et al.A gain-of-function mutation of JAK2 in myeloproliferative disorders.N Engl J Med,2005,352(17):1779-1790.
-
6Saharinen P,Vihinen M,Silvennnoinen O.Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.Mol Biol Ce11,2003,14(4):1448-1459.
-
7Schade AE,Wlodarski MW,Maciejewaki JP.Pathophysiology defined by altered signal transduction pathways:the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes.Cell Cycle,2006,5(22):2571-2574.
-
8Nagy ZS,Rui H,Stepkowski SM,et al.A preferential role for STATS,not constitutively active STAT3,in promoting survival of a human lymphoid tumor.J Immunol,2006,177 48):5032-5040.
-
9Goerttler PS,Kreutz C,Donauer J,et al.Gene expression profiling in polycythaemia vera:overexpresaion of transcription factor NF-E2.Br J Haematol,2005,12941):138-150.
-
10Kralovics R,Teo SS,Buser AS,et al.Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.Blood,2005,106(10):3374-3376.
二级参考文献13
-
1时昊,朱锋,张红,肖爱琴,张志瑢,王克强.急性非淋巴细胞白血病中CD117表达与化疗疗效的关系[J].中国癌症杂志,2006,16(3):165-168. 被引量:4
-
2Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-kit and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol, 2003, 121:775-777.
-
3Thiede C, Steudel C, Mohr B, et al. Analysis of FL33-activating mutation in 979 patients with acute myelogenous leukemia : association with FAB subtypes and identification of a sugroups with poor prognosis. Blood, 2002, 99:4326-4335.
-
4Meshinehi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood, 2003, 102:1474-1479.
-
5Wang YY, Zhou GB, Yin T, et al. AML1-ETO and c-kit mutation over-expression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A, 2005, 102: 1104-1109.
-
6Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv( 16 ) and t (8;21 ) : a Cancer and Leukemia Group B Study. J Clin Oncol, 2006, 24:3904-3911.
-
7Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-kit mutations in core binding factor leukemias: an Italian retrospective study. Blood, 2006, 107:3463-3468.
-
8Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene, 2006, 25: 1434-1436.
-
9Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet, 2002, 3 : 179-198.
-
10Liang DC, Shih LY, Huang CF, et al. Different cooperating mutation patterns of receptor tyrosine kinase/Ras/JAK2 between de novo AML1-ETO and CBF-MYHll acute myloid leukemia. Blood, 2007, 110 : 3487a.
共引文献6
-
1姚冬明,钱军,林江,陈芹,肖高飞,王雅丽,钱震,纪润璧,李云,杨静.高分辨率熔解曲线分析法检测急性髓系白血病c-kit基因突变[J].中华血液学杂志,2011,32(1):21-24. 被引量:3
-
2姜乃可,贾祝霞,晁红颖,周民,陈涛,卢绪章,张日,杨建和,肖溶,岑岭.骨髓增生异常综合征患者IDH、JAK2、FLT3、NPM1和c-KIT基因突变的综合检测与分析[J].中华血液学杂志,2012,33(7):578-581. 被引量:7
-
3夏晶,陈苏宁,潘金兰,王琴荣,吴亚芳,王勇,张俊,沈娟,薛永权,阮长耿.20例t(8;21)复杂变异易位急性髓系白血病患者的临床和实验室研究[J].中国实验血液学杂志,2013,21(4):815-820. 被引量:1
-
4耿素霞,杜欣,翁建宇,黄欣,陆泽生,钟立业,郭荣,吴穗晶,吴萍.AML1-ETO阳性急性髓系白血病患者c-kit突变及其临床意义[J].中国实验血液学杂志,2013,21(4):839-842. 被引量:5
-
5刘洁,周民,晁红颖,姜乃可,卢绪章.急性单核细胞白血病患者分子遗传学特征分析[J].中国实用医药,2016,11(36):4-7. 被引量:2
-
6于景秋,薛胜利,李正,王隽,王超,储小玲,撖荣,陶涛,邱桥成,吴德沛.二代测序检测克隆性基因突变对RUNX1-RUNX1T1阳性急性髓系白血病的预后价值[J].中华血液学杂志,2020,41(3):210-215. 被引量:3
-
1冯宇锋,朱子玲,晁红颖,常惠荣,陈婉,宋铁梅,戴丽君.原发性血小板增多症90例患者JAK2基因突变的分析[J].中国血液流变学杂志,2009,19(2):230-233. 被引量:1
-
2费海荣,张日,陈苏宁,潘金兰,岑建农,薛永权.骨髓增殖性疾病137例患者JAK2基因突变的研究[J].中华内科杂志,2007,46(4):271-273. 被引量:15
-
3朱平.骨髓增殖性疾病JAK2基因突变的临床意义[J].中华医学杂志,2006,86(32):2243-2245. 被引量:14
-
4刘学文,马宏杰.JAK2 V617F突变与真性红细胞增多症的研究进展[J].中外医疗,2014,33(21):194-196. 被引量:2
-
5孙启鑫,温真真,朱志刚,王顺清,李庆山,应逸.骨髓增生异常综合征合并骨髓纤维化和Jak2基因突变1例[J].广东医学,2015,36(10):1496-1496.
-
6张海艳,翟晓文.JAK2基因突变在急性白血病中的研究进展[J].中国当代儿科杂志,2015,17(6):644-648. 被引量:5
-
7刘丽,李薇,刘念,庞磊,冯思霞,赵玲玲.Jak2基因突变的研究进展[J].中国实验血液学杂志,2009,17(6):1629-1632. 被引量:3
-
8木合拜尔.阿布都尔,刘虹,买买提力.依马木,张晓燕,安利,王晓敏.真性红细胞增多症患者JAK2 V617F基因突变及其意义[J].广东医学,2013,34(1):94-96. 被引量:2
-
9费海荣,张日,陈苏宁,潘金兰,岑建农,薛永权.骨髓增殖性疾病患者JAK2基因突变的研究[J].中国实用内科杂志,2007,27(S1):62-62.
-
10王冠宙,李稳蕾,王平.26例慢性骨髓增殖性肿瘤JAK2基因突变检测报告[J].医学信息(中旬刊),2011,24(3):842-842. 被引量:1